{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT06218251",
      "orgStudyIdInfo": {
        "id": "M22-974"
      },
      "organization": {
        "fullName": "AbbVie",
        "class": "INDUSTRY"
      },
      "briefTitle": "A Study to Evaluate Participant Satisfaction and Natural Outcomes Following Administration of BOTOX Cosmetic Injections in Adult Participants for Treatment of Upper Facial Lines",
      "officialTitle": "A Prospective, Multi-center, Open-label Study to Evaluate Subject Satisfaction and Natural Outcomes Following Administration of BOTOXÂ® (Botulinum Toxin Type A) Purified Neurotoxin Complex in Subjects With Upper Facial Lines (Glabellar Lines, Lateral Canthal Lines, and Forehead Lines)",
      "acronym": "UFL BOND 974"
    },
    "statusModule": {
      "statusVerifiedDate": "2025-11",
      "overallStatus": "COMPLETED",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2024-02-05",
        "type": "ACTUAL"
      },
      "primaryCompletionDateStruct": {
        "date": "2024-07-25",
        "type": "ACTUAL"
      },
      "completionDateStruct": {
        "date": "2024-12-17",
        "type": "ACTUAL"
      },
      "studyFirstSubmitDate": "2024-01-12",
      "studyFirstSubmitQcDate": "2024-01-12",
      "studyFirstPostDateStruct": {
        "date": "2024-01-23",
        "type": "ACTUAL"
      },
      "resultsFirstSubmitDate": "2025-07-07",
      "resultsFirstSubmitQcDate": "2025-08-01",
      "resultsFirstPostDateStruct": {
        "date": "2025-08-06",
        "type": "ACTUAL"
      },
      "lastUpdateSubmitDate": "2025-11-11",
      "lastUpdatePostDateStruct": {
        "date": "2025-11-24",
        "type": "ESTIMATED"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "SPONSOR"
      },
      "leadSponsor": {
        "name": "AbbVie",
        "class": "INDUSTRY"
      }
    },
    "oversightModule": {
      "oversightHasDmc": false,
      "isFdaRegulatedDrug": true,
      "isFdaRegulatedDevice": false,
      "isUsExport": false
    },
    "descriptionModule": {
      "briefSummary": "Facial lines that develop from repeated facial expression, such as glabellar lines (GL), lateral canthal lines (LCL), and forehead lines (FHL), are typically treated by selectively weakening specific muscles with small quantities of botulinum toxin. The purpose of this study is to evaluate participant satisfaction and natural outcomes following the administration of BOTOX Cosmetic in adult participants with upper facial lines (GL, LCL, and FHL).\n\nThis is an open-label study in which all participants will receive active study treatment. Around 100 adult participants with an assessment of moderate to severe GL, LCL, and FHL, will be enrolled at approximately 10 sites in the United States and Canada.\n\nParticipants will receive BOTOX Cosmetic as intramuscular injections to the glabellar lines, lateral canthal lines, and forehead lines at Day 1.\n\nParticipants will attend regular visits during the study. The effect of the treatment will be checked by medical assessments for side effects and questionnaires will be completed during regular study visits."
    },
    "conditionsModule": {
      "conditions": [
        "Upper Facial Lines"
      ],
      "keywords": [
        "Glabellar Lines",
        "Lateral Canthal Lines",
        "Forehead Lines",
        "BOTOX",
        "Botulinum Toxin Type A",
        "OnabotulinumtoxinA",
        "Upper Facial Lines",
        "Crows Feet Lines",
        "Wrinkles",
        "Facial Wrinkles",
        "Facial Rhytides"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "designInfo": {
        "allocation": "NA",
        "interventionModel": "SINGLE_GROUP",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "NONE"
        }
      },
      "enrollmentInfo": {
        "count": 100,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "BOTOX",
          "type": "EXPERIMENTAL",
          "description": "Participants will receive injections in the glabellar complex, in each of the lateral canthal area, and in the frontalis muscle on Day 1.",
          "interventionNames": [
            "Drug: BOTOX"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "BOTOX",
          "description": "Intramuscular Injections",
          "armGroupLabels": [
            "BOTOX"
          ],
          "otherNames": [
            "Botulinum Toxin Type A",
            "OnabotulinumtoxinA"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Percentage of Participants With Responder Status of 'Mostly Satisfied' or 'Very Satisfied' on the Facial Line Satisfaction Questionnaire (FLSQ) Follow Up Item 4 (Satisfaction With the Natural Look)",
          "description": "The FLSQ consists of 13 questions that assess treatment satisfaction and psychosocial impact. Participants assessed their satisfaction with upper facial lines using the FLSQ 5-point scale where: -2=Very dissatisfied and 2=Very satisfied.",
          "timeFrame": "Day 30"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Change From Baseline in Overall Score of the Participant's Assessment of FACE-Q Psychological Function",
          "description": "The FACE-Q Psychological Function is a 10-item scale that measures psychological function. The responses score ranges from 0 to 100. Higher scores reflect a better outcome.",
          "timeFrame": "Day 30"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* Moderate to severe Glabellar Lines, Lateral Canthal Lines, and Forehead Lines.\n* Sufficient visual acuity without the use of eyeglasses (contact lens use acceptable) to accurately assess their facial wrinkles.\n\nExclusion Criteria:\n\n* Presence or history of any medical condition that may place the participant at increased risk to BOTOX Cosmetic or interfere with the study evaluation.\n* Presence of tattoos, jewelry, or clothing which obscures or interferes with the target area of interest and cannot be removed.\n* History of known immunization or hypersensitivity to any botulinum toxin serotype.",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "stdAges": [
        "ADULT",
        "OLDER_ADULT"
      ]
    },
    "contactsLocationsModule": {
      "overallOfficials": [
        {
          "name": "ABBVIE INC.",
          "affiliation": "AbbVie",
          "role": "STUDY_DIRECTOR"
        }
      ],
      "locations": [
        {
          "facility": "Skin Wellness Dermatology - Homewood /ID# 248469",
          "city": "Birmingham",
          "state": "Alabama",
          "zip": "35209-8314",
          "country": "United States",
          "geoPoint": {
            "lat": 33.52066,
            "lon": -86.80249
          }
        },
        {
          "facility": "The Research Center at The Maas Clinic /ID# 256633",
          "city": "San Francisco",
          "state": "California",
          "zip": "94115-1809",
          "country": "United States",
          "geoPoint": {
            "lat": 37.77493,
            "lon": -122.41942
          }
        },
        {
          "facility": "Pacific Clinical Innovations /ID# 248467",
          "city": "Vista",
          "state": "California",
          "zip": "92083-6030",
          "country": "United States",
          "geoPoint": {
            "lat": 33.20004,
            "lon": -117.24254
          }
        },
        {
          "facility": "Kavali Plastic Surgery and Skin Renewal Center /ID# 248472",
          "city": "Atlanta",
          "state": "Georgia",
          "zip": "30328",
          "country": "United States",
          "geoPoint": {
            "lat": 33.749,
            "lon": -84.38798
          }
        },
        {
          "facility": "Tennessee Clinical Research Center /ID# 259161",
          "city": "Nashville",
          "state": "Tennessee",
          "zip": "37215-2885",
          "country": "United States",
          "geoPoint": {
            "lat": 36.16589,
            "lon": -86.78444
          }
        },
        {
          "facility": "Integrated Aesthetics - Spring /ID# 257738",
          "city": "Spring",
          "state": "Texas",
          "zip": "77388",
          "country": "United States",
          "geoPoint": {
            "lat": 30.07994,
            "lon": -95.41716
          }
        },
        {
          "facility": "SkinDC /ID# 248470",
          "city": "Arlington",
          "state": "Virginia",
          "zip": "22209",
          "country": "United States",
          "geoPoint": {
            "lat": 38.88101,
            "lon": -77.10428
          }
        },
        {
          "facility": "Skin Matters Medical Aesthetic Centre /ID# 249539",
          "city": "Vancouver",
          "state": "British Columbia",
          "zip": "V6M 4J2",
          "country": "Canada",
          "geoPoint": {
            "lat": 49.24966,
            "lon": -123.11934
          }
        },
        {
          "facility": "Project Skin MD - Ottawa /ID# 249718",
          "city": "Ottawa",
          "state": "Ontario",
          "zip": "K1K 2Z7",
          "country": "Canada",
          "geoPoint": {
            "lat": 45.41117,
            "lon": -75.69812
          }
        },
        {
          "facility": "Bertucci MedSpa Inc. /ID# 249757",
          "city": "Woodbridge",
          "state": "Ontario",
          "zip": "L4L 8E2",
          "country": "Canada",
          "geoPoint": {
            "lat": 43.78341,
            "lon": -79.59962
          }
        }
      ]
    },
    "referencesModule": {
      "seeAlsoLinks": [
        {
          "label": "Related Info",
          "url": "https://www.abbvieclinicaltrials.com/study/?id=M22-974"
        }
      ]
    },
    "ipdSharingStatementModule": {
      "ipdSharing": "YES",
      "description": "AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.",
      "infoTypes": [
        "STUDY_PROTOCOL",
        "SAP",
        "CSR"
      ],
      "timeFrame": "For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/",
      "accessCriteria": "Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/",
      "url": "https://vivli.org/ourmember/abbvie/"
    }
  },
  "resultsSection": {
    "participantFlowModule": {
      "groups": [
        {
          "id": "FG000",
          "title": "BOTOX",
          "description": "Participants will receive injections in the glabellar complex, in each of the lateral canthal area, and in the frontalis muscle on Day 1."
        }
      ],
      "periods": [
        {
          "title": "Overall Study",
          "milestones": [
            {
              "type": "STARTED",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "100"
                }
              ]
            },
            {
              "type": "COMPLETED",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "96"
                }
              ]
            },
            {
              "type": "NOT COMPLETED",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "4"
                }
              ]
            }
          ],
          "dropWithdraws": [
            {
              "type": "Lost to Follow-up",
              "reasons": [
                {
                  "groupId": "FG000",
                  "numSubjects": "4"
                }
              ]
            }
          ]
        }
      ]
    },
    "baselineCharacteristicsModule": {
      "populationDescription": "Modified Intent-to-Treat Population",
      "groups": [
        {
          "id": "BG000",
          "title": "BOTOX",
          "description": "Participants will receive injections in the glabellar complex, in each of the lateral canthal area, and in the frontalis muscle on Day 1."
        }
      ],
      "denoms": [
        {
          "units": "Participants",
          "counts": [
            {
              "groupId": "BG000",
              "value": "100"
            }
          ]
        }
      ],
      "measures": [
        {
          "title": "Age, Continuous",
          "paramType": "MEAN",
          "dispersionType": "STANDARD_DEVIATION",
          "unitOfMeasure": "years",
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "45.6",
                      "spread": "12.31"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "Sex: Female, Male",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "classes": [
            {
              "categories": [
                {
                  "title": "Female",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "71"
                    }
                  ]
                },
                {
                  "title": "Male",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "29"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "Ethnicity (NIH/OMB)",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "classes": [
            {
              "categories": [
                {
                  "title": "Hispanic or Latino",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "12"
                    }
                  ]
                },
                {
                  "title": "Not Hispanic or Latino",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "88"
                    }
                  ]
                },
                {
                  "title": "Unknown or Not Reported",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "Race (NIH/OMB)",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "classes": [
            {
              "categories": [
                {
                  "title": "American Indian or Alaska Native",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    }
                  ]
                },
                {
                  "title": "Asian",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "18"
                    }
                  ]
                },
                {
                  "title": "Native Hawaiian or Other Pacific Islander",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    }
                  ]
                },
                {
                  "title": "Black or African American",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "11"
                    }
                  ]
                },
                {
                  "title": "White",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "66"
                    }
                  ]
                },
                {
                  "title": "More than one race",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "5"
                    }
                  ]
                },
                {
                  "title": "Unknown or Not Reported",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    }
                  ]
                }
              ]
            }
          ]
        }
      ]
    },
    "outcomeMeasuresModule": {
      "outcomeMeasures": [
        {
          "type": "PRIMARY",
          "title": "Percentage of Participants With Responder Status of 'Mostly Satisfied' or 'Very Satisfied' on the Facial Line Satisfaction Questionnaire (FLSQ) Follow Up Item 4 (Satisfaction With the Natural Look)",
          "description": "The FLSQ consists of 13 questions that assess treatment satisfaction and psychosocial impact. Participants assessed their satisfaction with upper facial lines using the FLSQ 5-point scale where: -2=Very dissatisfied and 2=Very satisfied.",
          "populationDescription": "Modified Intent-to-Treat Population\n\nN is Number of subjects with observed measurements at the visit.",
          "reportingStatus": "POSTED",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "timeFrame": "Day 30",
          "groups": [
            {
              "id": "OG000",
              "title": "BOTOX",
              "description": "Participants will receive injections in the glabellar complex, in each of the lateral canthal area, and in the frontalis muscle on Day 1."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "95"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "86"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Change From Baseline in Overall Score of the Participant's Assessment of FACE-Q Psychological Function",
          "description": "The FACE-Q Psychological Function is a 10-item scale that measures psychological function. The responses score ranges from 0 to 100. Higher scores reflect a better outcome.",
          "populationDescription": "Modified Intent-to-Treat Population\n\nN is Number of participants with observed measurements at both baseline and the given visit.",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Standard Deviation",
          "unitOfMeasure": "units on a scale",
          "timeFrame": "Day 30",
          "groups": [
            {
              "id": "OG000",
              "title": "BOTOX",
              "description": "Participants will receive injections in the glabellar complex, in each of the lateral canthal area, and in the frontalis muscle on Day 1."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "83"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "20.1",
                      "spread": "17.96"
                    }
                  ]
                }
              ]
            }
          ]
        }
      ]
    },
    "adverseEventsModule": {
      "frequencyThreshold": "1",
      "timeFrame": "All-cause mortality and adverse event tables include events reported from the time of informed consent to the end of the study. The median time on follow-up was 182 days for BOTOX.",
      "eventGroups": [
        {
          "id": "EG000",
          "title": "BOTOX",
          "description": "Participants will receive injections in the glabellar complex, in each of the lateral canthal area, and in the frontalis muscle on Day 1.",
          "deathsNumAffected": 0,
          "deathsNumAtRisk": 100,
          "seriousNumAffected": 0,
          "seriousNumAtRisk": 100,
          "otherNumAffected": 19,
          "otherNumAtRisk": 100
        }
      ],
      "otherEvents": [
        {
          "term": "EAR PAIN",
          "organSystem": "Ear and labyrinth disorders",
          "sourceVocabulary": "MedDRA 27.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 100
            }
          ]
        },
        {
          "term": "CONJUNCTIVAL HAEMORRHAGE",
          "organSystem": "Eye disorders",
          "sourceVocabulary": "MedDRA 27.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 100
            }
          ]
        },
        {
          "term": "FACIAL DISCOMFORT",
          "organSystem": "General disorders",
          "sourceVocabulary": "MedDRA 27.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 100
            }
          ]
        },
        {
          "term": "BRONCHITIS",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 27.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 100
            }
          ]
        },
        {
          "term": "CELLULITIS",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 27.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 100
            }
          ]
        },
        {
          "term": "COVID-19",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 27.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 100
            }
          ]
        },
        {
          "term": "NASOPHARYNGITIS",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 27.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 100
            }
          ]
        },
        {
          "term": "URINARY TRACT INFECTION",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 27.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 100
            }
          ]
        },
        {
          "term": "CONTUSION",
          "organSystem": "Injury, poisoning and procedural complications",
          "sourceVocabulary": "MedDRA 27.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 100
            }
          ]
        },
        {
          "term": "FALL",
          "organSystem": "Injury, poisoning and procedural complications",
          "sourceVocabulary": "MedDRA 27.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 100
            }
          ]
        },
        {
          "term": "LIGAMENT SPRAIN",
          "organSystem": "Injury, poisoning and procedural complications",
          "sourceVocabulary": "MedDRA 27.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 100
            }
          ]
        },
        {
          "term": "BACK PAIN",
          "organSystem": "Musculoskeletal and connective tissue disorders",
          "sourceVocabulary": "MedDRA 27.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 2,
              "numAffected": 2,
              "numAtRisk": 100
            }
          ]
        },
        {
          "term": "DYSPLASTIC NAEVUS",
          "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
          "sourceVocabulary": "MedDRA 27.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 100
            }
          ]
        },
        {
          "term": "HEADACHE",
          "organSystem": "Nervous system disorders",
          "sourceVocabulary": "MedDRA 27.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 9,
              "numAffected": 6,
              "numAtRisk": 100
            }
          ]
        },
        {
          "term": "BROW PTOSIS",
          "organSystem": "Skin and subcutaneous tissue disorders",
          "sourceVocabulary": "MedDRA 27.1",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 100
            }
          ]
        }
      ]
    },
    "moreInfoModule": {
      "certainAgreement": {
        "piSponsorEmployee": false,
        "restrictiveAgreement": false
      },
      "pointOfContact": {
        "title": "AbbVie",
        "organization": "ABBVIE CALL CENTER",
        "email": "abbvieclinicaltrials@abbvie.com",
        "phone": "844-663-3742"
      }
    }
  },
  "documentSection": {
    "largeDocumentModule": {
      "largeDocs": [
        {
          "typeAbbrev": "Prot",
          "hasProtocol": true,
          "hasSap": false,
          "hasIcf": false,
          "label": "Study Protocol",
          "date": "2023-12-14",
          "uploadDate": "2025-07-07T16:18",
          "filename": "Prot_000.pdf",
          "size": 1156756
        },
        {
          "typeAbbrev": "SAP",
          "hasProtocol": false,
          "hasSap": true,
          "hasIcf": false,
          "label": "Statistical Analysis Plan",
          "date": "2025-03-17",
          "uploadDate": "2025-07-07T16:19",
          "filename": "SAP_001.pdf",
          "size": 356551
        }
      ]
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2025-12-02",
      "submissionTracking": {
        "firstMcpInfo": {
          "postDateStruct": {
            "date": "2025-07-24",
            "type": "ACTUAL"
          }
        }
      }
    },
    "interventionBrowseModule": {
      "meshes": [
        {
          "id": "D019274",
          "term": "Botulinum Toxins, Type A"
        }
      ],
      "ancestors": [
        {
          "id": "D001905",
          "term": "Botulinum Toxins"
        },
        {
          "id": "D008666",
          "term": "Metalloendopeptidases"
        },
        {
          "id": "D010450",
          "term": "Endopeptidases"
        },
        {
          "id": "D010447",
          "term": "Peptide Hydrolases"
        },
        {
          "id": "D006867",
          "term": "Hydrolases"
        },
        {
          "id": "D004798",
          "term": "Enzymes"
        },
        {
          "id": "D045762",
          "term": "Enzymes and Coenzymes"
        },
        {
          "id": "D045726",
          "term": "Metalloproteases"
        },
        {
          "id": "D001426",
          "term": "Bacterial Proteins"
        },
        {
          "id": "D011506",
          "term": "Proteins"
        },
        {
          "id": "D000602",
          "term": "Amino Acids, Peptides, and Proteins"
        },
        {
          "id": "D001427",
          "term": "Bacterial Toxins"
        },
        {
          "id": "D014118",
          "term": "Toxins, Biological"
        },
        {
          "id": "D001685",
          "term": "Biological Factors"
        }
      ]
    }
  },
  "hasResults": true
}